Sai Life Sciences Faces Tax and Interest Demand

Sai Life Sciences has received an order from the Income Tax department for assessment year 2020-21, demanding ₹2.54 crore in tax and ₹1.99 crore in interest. The demand stems from the alleged non-deduction of Tax Deducted at Source (TDS) on payments made to non-residents. An additional penalty amount is yet to be assessed by the department.

Company Plans Appeal, Expects No Material Impact

While Sai Life Sciences intends to appeal this tax demand, such disputes can introduce financial uncertainty. The company has stated it does not anticipate a material financial impact from this order, a position it has taken in previous tax matters. However, any unsuccessful appeal could lead to the actual payment of these amounts, potentially affecting cash flows and profitability.

About Sai Life Sciences

Sai Life Sciences operates as a full-service Contract Research, Development, and Manufacturing Organization (CRDMO) in the pharmaceutical services sector. It is recognized as one of the fastest-growing CRDMOs among its listed Indian peers, based on revenue and EBITDA compound annual growth rate (CAGR) from FY22 to FY24.

Previous Tax Disputes

This is not the first encounter Sai Life Sciences has had with tax authorities. In November 2025, the company announced it was filing an appeal against a substantial GST/IGST demand totaling approximately ₹20.84 crore in tax, ₹13.75 crore in interest, and ₹2.08 crore in penalty, also stating no material financial impact was expected. Previously, in June 2019, the company was involved in a Service Tax dispute related to its clinical pharmacology and research services.

Next Steps and Contingent Liability

Sai Life Sciences must now prepare and file an appeal against the Income Tax department's order. This action quantifies a contingent liability for tax and interest, pending the outcome of the appeal. The ultimate financial impact remains uncertain until the penalty is assessed and the appeal process is resolved.

Key Risks to Monitor

The primary risk is that the appeal may not be successful, leading to the actual payment of the tax, interest, and any levied penalty. The quantum of the penalty is yet to be determined, which could further increase the financial burden.

Industry Context and Competitors

Sai Life Sciences operates in the competitive Indian pharmaceutical and contract manufacturing landscape. Its peers include Divi's Laboratories, a leading API manufacturer; Laurus Labs, an integrated pharmaceutical company with strong API and CDMO capabilities; and Syngene International, a broad-based CRDMO. These companies function in highly regulated environments where compliance, including tax regulations, is crucial.

What Investors Are Tracking

Investors will be closely monitoring the progress of Sai Life Sciences' appeal, the final determination of any penalty by the assessing officer, and any further updates from the company regarding its legal strategy and financial projections related to this demand.